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Dual-targeting anti-angiogenic 
cyclic peptides as potential drug 
leads for cancer therapy
Lai Yue Chan1, David J. Craik1 & Norelle L. Daly2
Peptide analogues derived from bioactive hormones such as somatostatin or certain growth factors 
have great potential as angiogenesis inhibitors for cancer applications. In an attempt to combat 
emerging drug resistance many FDA-approved anti-angiogenesis therapies are co-administered with 
cytotoxic drugs as a combination therapy to target multiple signaling pathways of cancers. However, 
cancer therapies often encounter limiting factors such as high toxicities and side effects. Here, we 
combined two anti-angiogenic epitopes that act on different pathways of angiogenesis into a single 
non-toxic cyclic peptide framework, namely MCoTI-II (Momordica cochinchinensis trypsin inhibitor-II), 
and subsequently assessed the anti-angiogenic activity of the novel compound. We hypothesized 
that the combination of these two epitopes would elicit a synergistic effect by targeting different 
angiogenesis pathways and result in improved potency, compared to that of a single epitope. This 
novel approach has resulted in the development of a potent, non-toxic, stable and cyclic analogue with 
nanomolar potency inhibition in in vitro endothelial cell migration and in vivo chorioallantoic membrane 
angiogenesis assays. This is the first report to use the MCoTI-II framework to develop a 2-in-1 anti-
angiogenic peptide, which has the potential to be used as a form of combination therapy for targeting a 
wide range of cancers.
Over the past decade angiogenesis inhibitors have been a primary focus for cancer researchers, and understand-
ing the various pathways of angiogenesis is vital for the design and development of next-generation therapies1. 
Angiogenesis inhibitor drugs currently on the market include the antibody bevacizumab (AVASTIN), and the 
small molecule drugs sorafenib (NEXAVAR) and sunitinib (SUTENT)2. Although they have been widely used 
in chemotherapy for the treatment of various cancers, there are drawbacks to their use – both alone and in com-
bination therapies. In some cases these therapies can result in severe side effects, such as bleeding and clotting 
in arteries, which potentially lead to stroke or heart attack and hypertension3. Improvement of drug therapies is 
especially important for patients who are “high-risk” for surgical procedures, and those who may have complica-
tions near large blood vessels or other critical locations in the body4,5.
Peptides are an alternative class of molecules that have the potential to avoid some of the detrimental side 
effects of small-molecule drugs or antibodies, and the use and development of peptide-based therapeutics for can-
cer treatment is of particular interest in the pharmaceutical industry. The potential advantages of peptide-based 
therapies include lower immunogenicity than antibodies, and increased specificity towards the target of inter-
est compared to small molecules6,7. To date, cilengitide is the only peptide-based anti-angiogenic drug that has 
entered clinical trials8. More generally, only limited numbers of peptide-based drugs have reached the pharma-
ceutical market, as peptides tend to have lower stability than small molecule drugs and are subject to proteolysis. 
However, this limitation could potentially be overcome by cyclic disulfide-rich peptides9–11.
Cyclic disulfide-rich peptides are a group of intermediate-sized molecules with the potential to overcome 
some of the stability limitations of current biopharmaceutical drugs. Side effects associated with small mole-
cules might also be avoided through the higher target specificity of cyclic disulfide-rich peptides9,12. Some of 
the naturally occurring cyclic disulfide-rich peptides include kalata B1 (kB1)13, Momordica cochinchinen-
sis trypsin inhibitor-II (MCoTI-II)10, and sunflower trypsin inhibitor-1 (SFTI-1)11. These peptides have high 
thermal and enzymatic stability; for peptides such as kB1 and MCoTI-II, this stability is due to the presence of 
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the cyclic cystine knot (CCK), whereas for SFTI-1, stability results from the cyclic backbone and an extensive 
hydrogen-bonding network11.
The potential of these cyclic disulfide-rich peptides in pharmaceutical applications has recently been high-
lighted by the successful introduction of biologically active sequences into native cyclic peptide frameworks14 – a 
concept commonly known as ‘grafting’. The CCK framework contains six inter-cysteine loops and the SFTI-1 
framework has two loops. All of these loops can potentially be used for epitope insertion, but the variation in 
loop size and structure means some epitopes are more appropriate for particular loops than others. The concept 
of grafting a single epitope to a specific target has been previously demonstrated in kB1, MCoTI-I, MCoTI-II 
and SFTI-1 frameworks15,16 using a range of therapeutic epitopes, including a bradykinin B1 antagonist17, 
pro-angiogenic sequences18, and a Hdm2/HdmX antagonist19. These grafted peptides have enhanced stability 
compared to their linear counterparts, and the ability to suppress unwanted activities, such as hemolytic activity. 
In addition, a previous study on the anti-angiogenic epitope polyR showed inhibitory activity against vascular 
endothelial growth factor A (VEGF-A) when grafted into the kB1 framework20. We have further examined the 
versatility of the polyR epitope in other cyclic disulfide-rich frameworks.
Multi-targeted therapy is a new paradigm for developing the next generation of cancer therapeutics, which 
emerged because conventional single-targeted therapies often encounter drug resistance issues21. To address this 
issue we have grafted anti-angiogenic epitopes into different loops of cyclic disulfide-rich peptide frameworks 
to enable the design of potent dual-targeting angiogenesis inhibitors. The concept of designing dual-targeting 
angiogenesis inhibitors is illustrated in Fig. 1. The anti-angiogenic epitopes chosen for this study included: 
β-turn-derived peptides from somatostatin (SST-0122 and SST-0223), which target the somatostatin receptor spe-
cific to neuroendocrine tumors; a pigment epithelium-derived factor (PEDF)24–26, which specifically targets the 
PEDF receptor for anti-inflammatory skin disorders and suppresses VEGF endothelial proliferation; and, an 
anti-VEGF-derived peptide from phage display (polyR), which specifically inhibits the interaction of VEGF with 
the kinase domain receptor (KDR, VEGF-R2)27–29. These epitopes have been shown to inhibit cell proliferation, 
cell migration and tumor growth in in vitro and in vivo models with low micromolar and nanomolar inhibi-
tion22–25,27,28. Overall, this study resulted in the development of a promising dual-targeting angiogenesis inhibitor 
and proved the feasibility of using cyclic disulfide-rich frameworks for multiple loop grafting, which augurs well 
for the future use of these frameworks in designing peptide-based combination drug therapies for cancer patients.
Results
Design and characterization of “first-generation” SFTI-1 and MCoTI-II grafted peptides. Small 
linear epitopes with potent anti-angiogenic activity were grafted into the MCoTI-II and SFTI-1 frameworks, with 
the aim of enhancing the stability of the epitopes while maintaining or improving potency. All anti-angiogenic 
epitopes chosen for this study were derived from a range of human proteins (Fig. 1). The loops chosen for graft-
ing in SFTI-1 and MCoTI-II were based on previous successful examples18; in some cases, additional loops were 
used to explore structure–function relationships. A summary of the sequences of the epitopes, the native cyclic 
peptides, and the grafted peptides is given in Fig. 2.
Structural analysis using NMR spectroscopy. One-dimensional spectra were recorded on all of the 
grafted peptides and showed well dispersed peaks in the amide region (Supplementary Figs S1 and S2) consist-
ent with β -sheet containing peptides. Analysis of the secondary chemical shifts indicates that the grafted cyclic 
peptides have similar secondary structure to the native peptides. For example, the similarity in the secondary 
shifts of SFTI-SST-01 and SFTI-PEDF with the secondary shifts of native SFTI-1 indicates that both grafted cyclic 
peptides have similar structures to their native framework at all conserved residues, except at the locations of the 
grafted anti-angiogenic epitope (Fig. 3A). This conservation of native structure was also observed in grafted cyclic 
peptides with the MCoTI-II framework (Fig. 3B). Although the same epitopes were inserted into different cyclic 
frameworks, a difference in the secondary shifts was observed and can most probably be attributed to the different 
structural constraints or flexibility in the loops where the anti-angiogenic epitopes were inserted. The proline res-
idues in the grafted peptides had the same conformations as the native cyclic frameworks (SFTI-1 Pro 6-cis, Pro 
7-trans; MCoTI-II Pro 2-trans and Pro 15-trans) based on analysis of NOEs. The trans proline residues displayed 
strong NOEs between the δ H’s of the proline residues and the α H of the preceding residue, whereas the cis proline 
residue displayed a strong NOE between the α H of the proline and the α H of the preceding residue. In addi-
tion, the proline residue in PEDF adopted a trans conformation when inserted into both SFTI-1 and MCoTI-II 
frameworks. A chemical shifts table of MCoAA-02 is included as Supplementary Table S2 and deposited in the 
Biological Magnetic Resonance Data Bank with the accession number 26882 (http://www.bmrb.wisc.edu/). The 
two-dimensional TOCSY and NOESY spectra of MCoAA-02 are shown in Supplementary Fig. S3.
Linear epitopes, native and grafted cyclic peptides are non-toxic in a range of human cells. All 
peptides and drug controls (cilengitide, octreotide, and sunitinib) were screened in both hemolytic (Fig. 4) and 
cell cytotoxicity assays (a 2-h incubation; data not shown), and the grafted peptides were found to be non-toxic to 
mammalian and human red blood cells.
Grafted cyclic peptides showed specificity in inhibiting cell proliferation of HUVECs and can-
cer cells. Cell proliferation is one of the major processes to occur during tumor angiogenesis prior to cell 
migration21; thus, a reduction of cell proliferation during this time should inhibit new vascular growth to nearby 
tumor cells by stopping oxygen and nutrient supply. We determined the cell proliferation inhibitory activities of 
the linear epitopes, native and grafted cyclic peptides, and drug controls on HUVECs, MCF-7, PC-3, and HT-29 
cells (Table 1). Cilengitide showed good potency in inhibiting the proliferation of HUVECs, consistent with this 
cell line previously being shown to have high levels of expression of integrins30. Octreotide was included in the 
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study due to a previous report on its potent anti-angiogenic activity on HUVECs at concentrations within the 
range of 10−10–10−6 M; however, it had no effect on the proliferation of the cell lines tested in this study31. Full 
dose-response curves for all peptides listed in Table 1 are included in Supplementary Fig. S4. Neither of the native 
cyclic frameworks (SFTI-1 and MCoTI-II) inhibited cell proliferation in any of the cell lines at concentrations 
> 100 μ M. The linear epitopes and grafted peptides had varying degrees of inhibitory activity, likely due to the dif-
ferent types of receptors expressed within each cell line (the greater the number of types, the greater the number 
of potential targets), or the level at which the receptors are expressed (affecting the number of possible binding 
sites)30,31. Several grafted cyclic peptides showed better inhibition of proliferation compared to their linear coun-
terparts, potentially due to the greater stability conferred upon grafting into a cyclic framework. However, there 
are also examples where the grafted cyclic peptides had less inhibition on some cell lines in the proliferation assay 
compared to the linear form. It is possible the small peptides are restrained in the cyclic peptides in such a way as 
to inhibit binding to the appropriate target (Table 1).
Screening of peptides in VEGF-mediated HUVEC migration assay. Although the grafted cyclic 
peptides were inhibitory in the cell proliferation study, the ability to inhibit cell migration also plays an impor-
tant role in tumor angiogenesis. Consequently, all peptides, including cilengitide and octreotide, were tested 
in a VEGF-mediated HUVEC migration assay. VEGF was included as a positive control as it is a potent angio-
genic growth factor that stimulates HUVEC migration (taken as 100% in the assay). All first-generation peptides 
Figure 1. An overview of the screening process for the development of dual-targeting anti-angiogenic 
cyclic peptides, with a focus on the MCoTI-II framework. (A) Several potent anti-angiogenic sequences 
(pigment epithelium-derived factor (PEDF), somatostatin (SST) and polyR) were grafted onto SFTI-1 (PDB 
ID: 1JBL) and MCoTI-II (PDB ID: 1HA9) for initial in vitro bioactivity screening and NMR characterization. 
The PEDF sequence comprises residues Tyr 388 to Phe 394 from a human PEDF protein (Uniprot ID: P36955), 
two somatostatin mimetic sequences (SST-01 and SST-02) were derived from a human somatostatin receptor 
comprising residues Phe 109 to Thr 112, and an anti-VEGF mimetic (polyR) was derived from a phage display 
library27. The first tryptophan in the somatostatin epitopes was designed with a d-amino acid conformation, 
as a previous study showed this change is vital for its β-turn formation to selectively target SST2 and SST5 
receptors34. (B) Anti-angiogenic epitopes that gave potent activity among these first-generation cyclic peptides 
were selected, and further grafted into the MCoTI-II framework. (C) The second-generation peptides 
then underwent similar screening as the first-generation peptides. (D) Only the best analogues, along with 
corresponding single-targeting counterparts, were tested in in vivo assays and further characterized by NMR. 
The location of epitope insertion into SFTI-1 and MCoTI-II are indicated with red arrows. Different epitope 
insertions into loops of the SFTI-1 and MCoTI-II frameworks are showed using different colored circles (i.e. red 
(represents polyR), blue (represents PEDF), pink (represents SST-01), and green (represents SST-02)).
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showed better inhibition of HUVEC migration compared to their linear epitopes. Neither MCoTI-II nor SFTI-1 
showed any effect on HUVEC migration and were subsequently treated as negative controls. The MCoTI-II 
grafted peptides containing the SST-01 and PEDF epitopes showed 50% inhibition on HUVEC migration at 
0.005 μ M and between 1 to 5 μ M, respectively. The most potent SFTI-1 graft contained the PEDF epitope, which 
displayed 50% inhibition on HUVEC migration at 0.05 μ M, as shown in Fig. 5.
Design and characterization of dual-targeting grafted analogues. Second-generation analogues, 
containing two grafted epitopes, were designed based on the activity observed in cell proliferation and migration 
assays, as well as the NMR characterization studies. MCoTI-II was chosen as the second-generation framework 
for dual-epitope insertion because the larger number of loops and loops of different sizes offer greater scope for 
epitope insertion compared to SFTI-1. For the second-generation peptides (MCoAA-01 and MCoAA-02), the SST-
01 epitope was grafted into loop 5, consistent with the potent first-generation peptide, and the polyR and PEDF 
epitopes were grafted into loop 1 and loop 6, respectively. The locations of the polyR and PEDF epitopes were pri-
marily based on the first-generation cell migration assay results. The polyR and PEDF epitopes were flanked by gly-
cine residues to assist in peptide folding. The addition of the glycine residues maintained the original loop size of the 
native cyclic framework and were unlikely to have steric clashes during the folding process. Figure 1 illustrates the 
stages in the development of a potent dual-targeting cyclic peptide. A full list of peptide molecular masses is shown 
in Supplementary Table S1. All peptides were purified to > 95% before being used in the assays. An example of purity 
check and mass spectrometry data of MCoAA-02 is provided in Supplementary Fig. S5.
Both MCoAA-01 and MCoAA-02 had native-like structures based on NMR analysis. For MCoAA-02, the 
secondary shifts of the inserted anti-angiogenic epitope in loops 5 and 6 (Fig. 3B) were comparable to those 
grafted cyclic peptides with single anti-angiogenic epitopes (i.e., MCo-SST-01 and MCo-PEDF). Interestingly, 
MCoAA-01 and MCoAA-02 are capable of targeting particular cell lines with higher potency than peptides with 
a single epitope insertion. MCoAA-01 inhibited HUVEC proliferation with a higher potency than MCo-SST-01 
and MCo-PEDF. Similarly, MCoAA-02 inhibited HT29 cell proliferation more potently than MCo-SST-01 
and MCo-PEDF. However, there are exceptions in some cell lines where a single epitope insertion inhibited 
cell proliferation more potently compared to the dual-targeting peptides. These differences might be related to 
Figure 2. Sequences of grafted peptides with corresponding epitopes and native cyclic peptide frameworks. 
First-generation grafted cyclic peptides were designed with a single anti-angiogenic epitope inserted into a 
single loop. For the second-generation grafted cyclic peptides, two anti-angiogenic epitopes were inserted into 
two separate loops. Chosen anti-angiogenic epitopes are highlighted in bold. d-tryptophan is represented by ‘w’.
www.nature.com/scientificreports/
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variable expression levels of targeted receptors on these cell lines. MCoAA-02 was observed to be the most potent 
second-generation dual-targeting cyclic peptide, with 50% inhibition of HUVEC migration at 1 nM (Fig. 5T); for 
cilengitide, the same degree of inhibition required a concentration of 1 μ M (Fig. 5L). Images of the final step in 
the cell migration assay with MCoAA-02, prior to absorbance reading, are shown in Supplementary Fig. S7. Our 
data correlate well with that supplied by the manufacturer, with 10 μ M of cilengitide resulting in 100% inhibition 
of HUVEC attachment on vitronectin and fibronectin. Sunitinib, a potent multi-targeted tyrosine kinase small 
molecule inhibitor32, was also tested at 10 μ M and showed 100% inhibition of HUVEC migration (Supplementary 
Fig. S8A), which was similar to the effect of cilengitide and MCoAA-02 at this concentration. By contrast, octre-
otide showed a lower potency compared to cilengitide and MCoAA-02 between 1–10 μ M.
The effect of the potent dual-targeting cyclic peptide MCoAA-02 on blood vessel growth in the 
in vivo CAM model. Based on the potency of MCoAA-02 in the cell assays, it was also tested in a CAM assay 
to determine the effect on blood vessel growth in vivo (Fig. 6A). Octreotide, cilengitide and selected grafted cyclic 
peptides were included for comparative purposes, and VEGF (0.3 nM) was used as a positive control. To evaluate 
the inhibitory effect of these peptides on blood vessel growth, VEGF was added simultaneously to all peptides 
during the assay. Peptides were tested at 10 μ M, as most grafted cyclic peptides showed more than 50% inhibition 
in the cell migration assay at this concentration, with the exception of MCoAA-02, which was tested at concen-
trations ranging from 0.001 μ M to 10 μ M. MCoAA-02 more potently inhibited blood vessel growth compared to 
analogues with only single anti-angiogenic epitope insertions. An improvement in blood vessel growth inhibition, 
by approximately 42%, was observed for MCoAA-02 compared to MCo-PEDF. Although MCoAA-02 was not as 
potent as cilengitide in inhibiting blood vessel growth, it showed comparable results to octreotide at 10 μ M. In 
addition, MCoAA-02 was capable of inhibiting approximately 50% of blood vessel growth at 100 nM (Fig. 6A). 
Sunitinib was also tested and found to be more potent than cilengitide and octreotide at 10 μ M (Supplementary 
Figure 3. Structural analysis using NMR. (A) Comparison of SFTI-1 α H secondary shifts. (B) Comparison 
of MCoTI-II α H secondary shifts. All 2D NMR spectra were recorded at 298 K. All anti-angiogenic sequences 
are written in red and the regions for comparing native and grafted sequence are outlined by red dotted boxes. 
Disulfide bond connectivity is highlighted in yellow, and bold lines are used represent the cyclic nature of the 
peptides. Each cysteine is labeled with a Roman numeral and each loop is represented with the letter ‘L’. The 
loop of insertion of an anti-angiogenic sequence is circled in red for both SFTI-1 and MCoTI-II structures. All 
spectra were assigned using CCPNMR46 and each of the amino acid spin systems were specifically assigned 
based on Wuthrich et al.47. The α H secondary shifts were analyzed by subtracting the random coil 1H NMR 
chemical shifts of Wishart et al.48 from the experimental α H chemical shifts. The 3D molecular structure of 
SFTI-1 and MCoTI-II were illustrated using MOLMOL49.
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Fig. S8B,C). A comparison of excised CAM images of MCoAA-02 (0.001, 0.1 and 10 μ M), cyclic frameworks 
(MCoTI-II and SFTI-1), cilengitide, octreotide, and VEGF is shown in Fig. 6B.
Peptide stability assessment in human serum. The stability of peptides tested in the CAM assay 
was examined against human serum for 24 h. All peptides were stable when subjected to human serum except 
PEDF, a short linear peptide, which was degraded within 4 h, as expected. Interestingly, SST-01, which contains 
a d-amino acid, was found to be more stable than PEDF. The stability of MCoAA-02 was compared to sunitinib 
Figure 4. Hemolytic assay. Comparison of percentage hemolysis against human red blood cells for all peptides. 
Melittin was used as a positive control with 100% hemolysis. Drug controls (cilengitide, octreotide, and 
sunitinib) were also included in the assay. All data are shown as mean ± SD (n = 3).
Peptides
IC50 (μΜ)  ± S.D.; 48 hours
HUVEC MCF-7 PC3 HT-29
SST-01 57.54 ± 0.04 > 100 > 100 > 100
SFTI-SST-01 18.32 ± 0.05 46.07 ± 0.05 > 100 45.38 ± 0.03
MCo-SST-01 17.12 ± 0.05 > 100 85.44 ± 0.08 74.13 ± 0.07
SST-02 > 100 > 100 > 100 > 100
SFTI-SST-02 > 100 55.13 ± 0.07 > 100 43.29 ± 0.04
MCo-SST-02 > 100 70.61 ± 0.11 83.55 ± 0.20 58.89 ± 0.09
PEDF 19.40 ± 0.08 > 100 > 100 > 100
SFTI-PEDF 27.89 ± 0.11 > 100 > 100 > 100
MCo-PEDF 50.16 ± 0.15 53.44 ± 0.14 39.11 ± 0.07 35.22 ± 0.08
polyR 44.64 ± 0.03 83.51 ± 0.46 > 100 > 100
SFTI-polyR-L1 > 100 28.72 ± 0.15 > 100 82.27 ± 0.13
SFTI-polyR-L2 > 100 41.84 ± 0.07 > 100 > 100
MCo-polyR-L1 > 100 > 100 > 100 > 100
MCo-polyR-L6 34.95 ± 0.03 > 100 > 100 52.89 ± 0.11
MCoAA-01 10.83 ± 0.09 45.01 ± 0.16 > 100 40.12 ± 0.13
MCoAA-02 27.06 ± 0.06 > 100 35.44 ± 0.13 19.75 ± 0.07
SFTI-1 > 100 > 100 > 100 > 100
MCoTI-II > 100 > 100 > 100 > 100
cilengitide 4.69 ± 0.06 > 100 > 100 84.68 ± 0.13
octreotide > 100 > 100 > 100 > 100
sunitinib 19.10 ± 0.46 17.07 ± 0.11 16.24 ± 0.26 1.43 ± 0.24
Table 1.  Cell proliferation inhibitory activity of all grafted and native peptides on HUVECs and cancer 
cells.
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and MCoTI-II using the method described by Ji and colleagues19. Although MCoAA-02 was found to be slightly 
less stable than its native framework (MCoTI-II), more than 75% of this peptide remained in the serum over 24-h, 
Figure 5. Cell migration on VEGF-mediated HUVECs. The percentage of HUVEC migration was analyzed 
using Prism Version 6 (GraphPad). (A–T) VEGF was used as a positive control with 100% HUVEC migration. 
All peptides were tested at concentrations ranging from 0.001–50 μ M except for cilengitide and octreotide, 
which were tested in 10-fold dilutions from 10 μ M. Peptides were added in the presence of 0.3 nM VEGF 
(bottom chamber). Data are shown as mean ± SD (n ≥ 3). Data were normalized to the mean VEGF control. 
P-values are represented as follows: ****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01, and *p ≤ 0.05. A one-way ANOVA 
with Dunnett’s post-test using a multiple comparison test was used for statistical analysis.
www.nature.com/scientificreports/
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Figure 6. Chorionallantoic membrane and stability assays. (A) Comparison of blood vessel count of the 
linear and grafted peptides. Error bars indicate ± SD (n ≥ 6). The dotted line indicates ~50% inhibition 
of blood vessels. A one-way ANOVA with Dunnett’s post-test using a multiple comparison test was used 
for statistical analysis. In addition, unpaired t-test was used to test the significance of MCoAA-02 against 
MCo-SST-01 and MCo-PEDF. ****p ≤ 0.0001 and ***p ≤ 0.05. All peptides were compared to 0.3 nM 
VEGF (highlighted in grey), which is represented as 100% blood vessel growth. (B) This diagram shows the 
blood vessel growth of MCoAA-02 at various concentrations compared to the cyclic frameworks SFTI-1 
and MCoTI-II in the CAM assay. VEGF was used as the positive control, and octreotide and cilengitide as 
the negative controls. All images were taken with an original magnification of x16 on an Olympus SZX12 
dissecting microscope with a light box. DP capture and DP manager software packages were used during 
image acquisition. (C) This graph illustrates the percentage of peptide remaining over 24 h in the serum 
stability assay. All compounds showed better stability than the linear PEDF peptide (highlighted with red 
dashed lines). All data are represented as mean ± SD and were recorded in triplicate. Peptides labeled with 
an asterisk (*) were tested using the same method except with an additional step – dissolving the centrifuged 
pellet with 8 M guanidinium chloride before RP-HPLC analysis.
www.nature.com/scientificreports/
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which was approximately 20% higher than the percentage of sunitinib that remained after the same amount of 
time (Fig. 6C). Overall, results from this assay showed the native cyclic frameworks and all grafted cyclic peptides 
to be remarkably stable.
Discussion
Peptide therapeutics are known to have excellent selectivity and efficacy, low toxicity, and lower production costs 
than antibodies; however, they are prone to many challenges, including proteolytic instability and short in vivo 
half-lives33. These challenges can potentially be overcome by a range of chemical modifications to improve their 
physicochemical properties33. Despite these approaches for improving stability, many FDA-approved drugs are 
either small molecules or antibodies in the anti-angiogenic field, with only two cyclic peptide-based drugs – cilen-
gitide and octreotide – currently in late-stage clinical trials2 or on the market34, respectively. These developments 
suggest that peptide-based anti-angiogenic therapeutics is an area of potential growth.
One approach for improving stability of bioactive peptides is to conjugate them with more stable molecules. 
However, when short bioactive epitopes are conjugated externally on a molecule, they are more susceptible to 
degradation, as they are more readily accessible by enzymes and typically require further chemical modification 
to achieve acceptable pharmacokinetic properties35. Based on this limitation, our study aimed to explore how 
short anti-angiogenic epitopes can be cyclized within a single framework to improve stability and bioactivity. 
In addition, a dual-targeting strategy was also explored to examine the feasibility of incorporating two short 
anti-angiogenic epitopes into a single framework. As in the recent use of a dual-targeting strategy to target an 
epidermal growth factor receptor mutation in non-small-cell lung cancer patients by combining two individual 
drugs (i.e., afatinib and cetuximab), resulting in dramatic inhibition of tumor growth. Cetuximab alone showed 
significant suppression of tumors with the L858R mutation but only a slight response to tumors with the T790M 
mutation, highlighting the advantage of using the combination therapy36.
Many new opportunities for the development of peptide therapeutics are likely to arise from multifunctional 
peptides, and this is an area that needs further exploration33. Limited studies have used the dual-targeting strategy 
with cyclic, disulfide-rich frameworks; indeed, there are only a few examples of bi-functional peptides using cyclic 
frameworks37,38. Previous examples in this area have demonstrated the insertion of two similar epitopes target-
ing an identical receptor, as summarized in Fig. 7A. Although an increase in activity was observed compared to 
their corresponding singly grafted peptides, they did not show comparable or better effects compared to drug 
controls. In the current study, we demonstrated the rational design of second-generation dual-targeting cyclic 
anti-angiogenic peptides with two different grafted epitopes. Both grafted peptides produced nanomolar potency 
in both in vitro and in vivo studies, and showed comparable effects to cyclic peptide drug controls and higher 
stability in human serum than the orally active sunitinib.
All peptides used in this study were non-toxic to either cancer or normal cells, which allowed further 
investigation on the bioactivity of these peptides in a range of assays. An increase in the inhibitory activity of 
cell migration studies was observed on grafted peptides when compared to the activity of their correspond-
ing anti-angiogenic epitopes. This increase in potency is probably due to the increase in stability from grafting 
the epitopes into a cyclic framework. In this study, we have also demonstrated grafting epitopes into different 
locations of the same or different frameworks resulted in different biological effects. For example, differences 
in potency were observed for the polyR epitope when inserted into different loops of the same framework. This 
suggests that to gauge the best location of epitope insertion, a thorough understanding of the native framework 
structure is essential and screening using a range of assays to identify the location that results in the most signif-
icant increase in activity is important for the design of dual-targeting cyclic peptides. Among the grafted cyclic 
peptides, the dual-targeting MCoAA-01 and MCoAA-02 peptides were the most potent in the cell proliferation 
studies, with inhibition observed for several cell lines similar to the inhibitory effects in drug controls such as 
cilengitide and sunitinib. In particular, MCoAA-01 and MCoAA-02 most potently affected HUVECs and HT-29 
cells, respectively. This can be explained by the expression of SST and PEDF receptors in these cell lines, both of 
which are required for these dual-targeting peptides39. When these peptides were examined in the cell migration 
assay, MCoAA-02 exhibited greater potency than MCoAA-01. At 50% inhibition of HUVEC migration, MCoAA-
02 exerted 1000-fold higher potency than cilengitide; hence, it was further characterized in in vivo studies.
Given that MCoTI-II did not inhibit blood vessel growth in the CAM assay, it appears the anti-angiogenic 
activity of MCoAA-02 is derived solely from the grafted epitopes and not the cyclic framework. Furthermore, 
MCoAA-02 was more active in the CAM assay than MCo-SST-01 or MCo-PEDF, suggesting the inhibitory effect 
of blood vessels growth on MCoAA-02 could either be due to an additive or synergistic effect. More studies will 
be required in future to determine the specific effect of this peptide. Angiogenesis inhibition and tumor growth 
regulation events are both indirect effects of somatostatin. Therefore, MCoAA-02 could potentially have an indi-
rect effect in regulating VEGF on endothelial or tumor cells by inhibiting signaling events downstream of the 
SST and PEDF receptors, which results in the suppression of cell proliferation and migration. This hypothesis is 
supported by studies by Craword40 and Rai and colleagues41, who suggested that the anti-angiogenic effect caused 
by PEDF could be due to the suppression of pro-angiogenic miRNAs (e.g., miR-126, miR-23b and miR-27b). They 
suggest that blocking of these miRNAs leads to inhibition of endothelial cell proliferation, and the blocking of 
the SST receptor activates downstream signaling cascades such as MAPK or ERK pathways, and protein tyrosine 
phosphatases, which could lead to cell cycle arrest.
A schematic diagram outlining our proposed mechanism of action of MCoAA-02 on endothelial and tumor 
cells is shown in Fig. 7B. We propose that MCoAA-02 could inhibit cell proliferation of cancer and endothelial 
cells, followed by the inhibition of endothelial cell migration to nearby tumor cells and ultimately block nutri-
ent supply. Together, these events could result in the inhibition of blood vessel growth, consistent with the data 
from the CAM assay. Furthermore, MCoAA-02 could indirectly regulate VEGF on endothelial or tumor cells 
by inhibiting signaling events downstream of the SST and PEDF receptors, resulting in the suppression of cell 
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proliferation, migration and blood vessel growth. In contrast, in the absence of MCoAA-02 during an angiogene-
sis event, VEGF acts as a potent angiogenesis growth factor by binding to its corresponding receptor, VEGFR and 
stimulating cell proliferation, migration and blood vessel growth, as shown in Fig. 7B.
Apart from the biological activities of these peptides, peptide stability is also an important factor when design-
ing new peptide therapeutics, as it can enhance the probability of success in pharmacokinetic studies. Despite the 
significant number of residue changes in MCoAA-02 compared to MCoTI-II, both are stable in human serum 
over 24-h. This similarity in stability is presumably related to the similarities in structure reflected in the chemical 
shifts. Interestingly, MCoAA-02 was more stable in human serum than sunitinib. The stability of MCoAA-02 
combined with its lack of toxicity to normal or cancerous cells highlights its potential as a candidate for the 
design of dual- or multi-targeting peptide therapeutics targeting cancer applications. PEDF and SST-01 epitopes 
have also been implicated in treating ocular vascular diseases such as diabetic retinopathy40–43, suggesting that 
MCoAA-02 might also have applications in this field.
Although there are examples of combinatory approaches based on somatostatin, which include the con-
jugation of somatostatin to different chemotherapy drugs such as camptothecin and methotrexate, result-
ing in improved efficacy with fewer side effects39, this is the first study combining a somatostatin epitope with 
another anti-angiogenic epitope in a single cyclic disulfide-rich framework. This study thus potentially opens 
up new possibilities of using cyclic disulfide-rich frameworks as an alternative strategy for the development of 
next-generation peptide-based combination therapies. A further understanding of the specific mechanism of 
action on endothelial and cancer cells, along with in vivo mouse model studies, could also enhance its relevance 
Figure 7. A comparison of recent work using cyclic disulfide-rich frameworks for bi-functional studies 
and a schematic overview of how MCoAA-02 could inhibit the angiogenic process. (A) A comparison of 
dual-targeting peptides; specifically, a comparison of the findings of this study to previous work using cyclic 
disulfide-rich peptide frameworks originating from plant and animal sources. Previous work focused only on 
grafting two identical epitopes. Our work is the first utilizing the MCoTI-II cyclic framework for the insertion 
of two different anti-angiogenic targets. (B) Schematic diagram depicting how MCoAA-02 has the potential 
to act as a dual-targeting cyclic peptide by blocking indirect signaling pathways to exert a synergistic anti-
angiogenic effect.
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in a clinical setting. In addition, applying this strategy to other cyclic frameworks could lead to applications in a 
wide range of human diseases.
Materials and Methods
Peptide synthesis. Grafted peptides (all peptides listed in Table 1 except linear anti-angiogenic epitopes 
and MCoTI-II) and SFTI-1 were synthesized using solid-phase peptide synthesis on a CS Bio synthesizer 
using Boc chemistry. Peptides were constructed on Boc-Gly-PAM resin (Chem-Impex International) with 
S-tritylmercaptopropionic acid (Peptides International) as a linker using N,N,N′,N′-tetramethyl-O-(6-chloro-
1H-benzotriazol-1-yl)uronium hexafluorophosphate (HCTU) for amino acid activation. Linear peptide ana-
logues (polyR, PEDF, SST-01, SST-02) were synthesized using Fmoc chemistry on a Symphony microwave 
synthesizer using chlorotrityl chloride resin. Peptides made using Boc chemistry were cleaved from the resin 
using hydrogen fluoride with p-cresol as a scavenger at 0 to 5 °C for 1 h. Fmoc-synthesized peptides were cleaved 
using a mixture of 95% trifluoroacetic acid (TFA)/2.5% triisopropylsilane/2.5% H2O. The TFA was removed by 
rotary evaporation and the residue partitioned between 50% acetonitrile in water containing 0.1% TFA and cold 
diethyl ether. All grafted peptides and linear peptides were synthesized on a 0.5 mmol scale. The aqueous layer 
was lyophilized and the resulting crude peptides were purified using reverse-phase HPLC (RP-HPLC). MCoTI-II 
was isolated from M. cochinchinensis seed extract, as described by Chan et al.44. Cilengitide (EMD 121974; cat-
alog no. S7077; MW: 588.66) and octreotide acetate (SANDOSTATIN; catalog no. P1017; MW: 1019.28) were 
purchased from Selleck Chemicals. Both drugs are cyclic peptide mimetics. Sunitinib malate, a small molecule 
multi-targeted receptor tyrosine inhibitor, was purchased from LC laboratories (SUTENT; catalog no. S-8803; 
M.W: 532.56).
Peptide purification and folding conditions. Crude peptides obtained from either plant extracts or 
chemical synthesis were purified using a series of Phenomenex C18 columns on RP-HPLC. Gradients of 1%/min 
of 0–80% solvent B (90% MeCN in 0.045% TFA in H2O) and solvent A (aqueous 0.05% TFA in H2O) were used 
and the eluent was monitored at 215 and 280 nm. Peptide purity was examined on a Nexera UHPLC (Shimadzu) 
with a flowrate of 0.4 mL/min on a 0.8 mL/min Agilent column using a 2% gradient of 0–50% solvent B and 
masses were determined by electrospray mass spectrometry. All peptides used in assays had > 95% purity. Folding 
trials were carried out using 1 mg/mL aliquots of peptide in various folding buffers of different pHs, as well as 
different concentrations of ammonium bicarbonate and dimethyl sulfoxide (DMSO). The optimal conditions for 
peptide folding were as follows: SFTI-1 grafted peptides were folded in two steps: cyclization with 0.1 M ammo-
nium bicarbonate (pH 8.0)/0.1 M TCEP, then oxidation in 0.1 M ammonium bicarbonate (pH 8.0); MCoTI-II 
grafted peptides were folded in a one-pot oxidation solution of 0.1 M ammonium bicarbonate (pH 8.5) except for 
MCo-SST-01, MCo-SST-02, MCoAA-01 and MCoAA-02, which required the addition of 10% DMSO. Examples 
of LC-MS traces of folded MCoAA-01 and MCoAA-02 with the above conditions are provided in Supplementary 
Fig. S6.
Cell culture. HUVECs (human umbilical vein endothelial cells) were cultured in EGM™ -2 BulletKit™ sup-
plemented with SingleQuots™ (supplements: growth factors, cytokines, antibiotics; Lonza) and 10% FBS (catalog 
no. FFBS-500; Scientifix). Both HT-29 and MCF-7 cells were cultured in 10% FBS/DMEM (Dulbecco’s Modified 
Eagle Medium) with 1% penicillin–streptomycin (5000 U/mL; Life Technologies), whereas PC3 cells (prostate 
cancer cells) were cultured in 10% FBS/RPMI (Roswell Park Memorial Institute) 1640 with 1% penicillin–strep-
tomycin (5000 U/mL; Life Technologies). All cells were maintained at 37 °C in 5% CO2.
Cell cytotoxicity and proliferation assays on HUVECs (non-cancerous) and cancerous cells. 
Cell cytotoxicity and proliferation assays were performed using similar methods to those described by Chan et 
al.45. All cells were maintained using the media conditions described above, and passages two to ten were used 
for all cell lines. For all cell lines, 5.0 × 103 cells/well (100 μ L) and 1.5 × 103 cells/well (100 μ L) were used for cell 
cytotoxicity and cell proliferation assays, respectively. All peptides (10 μ L, at final concentrations ranging from 
0.05–100 μ M) and drugs, which included cilengitide, octreotide and sunitinib (at final concentrations ranging 
from 0.00001–100 μ M), were used in both assays. Triton X-100 (0.1% (v/v); 10 μ L) was used as a positive control. 
Cells were treated with fresh media the day after plating, before the addition of peptides, followed by a subsequent 
2-h and 48-h incubation for cell cytotoxicity and cell proliferation, respectively. After different incubation peri-
ods, 3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) (10 μ L; 5 mg/mL in PBS) was added, 
and cells were incubated for a further 4 h. The supernatant was then removed and 100 μ L DMSO added to solu-
bilize formazan salts. Experiments were performed in triplicate. Cell numbers were recorded at 600 nm. All data 
represent average mean ± SD.
Transwell migration assay using HUVECs. A cell migration assay was performed as described by Chan 
et al.45 HUVECs between passages three and ten were used. Briefly, initial peptide concentrations of 10–500 μ M 
were prepared for all peptides except SFTI-SST-01, MCo-SST-01, SFTI-SST-02, MCo-SST-02, SFTI-PEDF, 
MCo-PEDF (0.01–500 μ M), cilengitide, octreotide, and MCoAA-02 (1 × 10−7 M–100 μ M). To the apical well, 
100 μ L of 1 × 105 cells/well were seeded and 600 μ L of medium supplemented with or without 0.3 nM VEGF 
(Sigma, catalogue no. V7259) was added to the basolateral well. The well containing cells with 0.1% FBS/EGM-2 
basal medium was used as a negative control, and the well containing cells with 0.3 nM VEGF was used as a 
positive control. All peptides were stimulated with 0.3 nM VEGF. Experiments were done in triplicate. All data 
represent mean ± SD. Prism Version 6 software (GraphPad) was used for statistical analysis. A one-way analysis 
of variance (ANOVA) with Dunnett’s multiple comparison test was applied in the analysis.
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Hemolytic assay. Human red blood cells were used to assess the toxicity of the peptides. Peptides and melit-
tin were tested at concentrations ranging from 0.05–50 μ M and 0.015–2 μ M, respectively. Cilengitide, octreo-
tide and sunitinib were tested at 10-fold dilutions from 0.00001–10 μ M. These experiments were performed as 
described previously44.
Peptide stability assay. The overall procedures used to assess peptide stability are based on those described 
previously by Chan et al.18 and Ji et al.19. A peptide concentration of 300 μ M was used, and time points taken at 0, 
2, 4, 8, 16, and 24 h. The stability of sunitinib was also examined using this method, except an additional step was 
added after the final centrifugation step, whereby the pellet was dissolved in 8 M guanidine hydrochloride (300 μ L) 
prior to analysis with RP-HPLC; this additional step was adapted from Ji et al.19. Supernantants were analyzed on 
an Agilent RP-HPLC using a linear 1%/min gradient of 0–50% solvent B with a 0.3 mL/min Phenomenex column. 
Peak height was used for integration of data at 215 nm and each experiment was performed in triplicate.
Inhibition of blood vessel growth using an in vivo CAM model. The chorioallantoic membrane 
(CAM) assay was performed as described by Chan et al.18. Briefly, fertilized quail (Cortunix cortunix) eggs were 
purchased from a local supplier (Jimboomba, Queensland, Australia) and incubated at 37 °C for 4 days in a 
humidified incubator prior to the start of the assay. All peptides were tested at 10 μ M, except MCoAA-02, which 
was tested at concentrations ranging from 0.001 μ M to 10 μ M with the addition of VEGF (final concentration: 
0.3 nM). VEGF solution and DMEM were used as positive and negative controls, respectively. Images were taken 
on an Olympus SZX12 dissecting microscope with an original magnification of x16. DP capture and DP manager 
software packages were used during image acquisition. Blood vessel number was quantified by eye, using a hand 
tally counter. A one-way ANOVA was applied for the statistical comparison analysis using Prism Version 6 soft-
ware (GraphPad). Each test peptide was compared with the positive control, and results were represented as mean 
blood vessel count. P < 0.05 was considered significant. All data represents average mean ± SD (n ≥ 6).
NMR spectroscopy. Samples were dissolved in 90% H2O/10% D2O (D2O; 99.9% purity; Cambridge 
Isotope Laboratories, Woburn, MA) with a final concentration of 1 mM at pH 5.5. 4,4-Dimethyl-4-silapentane-
1-sulfonic acid (DSS) was used as a chemical shift reference for spectral calibration. One-dimensional (1H) and 
two-dimensional (TOCSY and NOESY) spectra were recorded for all native and grafted peptides at 298 K on 
a Bruker Avance 600 MHz spectrometer, with mixing times of 200–300 ms for NOESY experiments. All spec-
tra were assigned using CCPNMR46. All amino acid spin systems were specifically assigned based on Wuthrich 
et al.47. For the α H secondary shifts, these were analyzed based on subtracting the random coil 1H NMR chemical 
shifts of Wishart et al.48 from experimental α H chemical shifts. The three-dimensional molecular structure of 
SFTI-1 and MCoTI-II were illustrated using MOLMOL49.
Statistical analysis. Results are expressed as mean ± standard deviation (SD) of the mean. Statistical sig-
nificance was evaluated with one-way ANOVA followed by Dunnett’s multiple comparison test, using GraphPad 
Prism Version 6 software.
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